Cullinan Therapeutics Operating Expenses 2020-2025 | CGEM

Cullinan Therapeutics operating expenses from 2020 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Cullinan Therapeutics Operating Expenses 2020-2025 | CGEM

Cullinan Therapeutics operating expenses from 2020 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.3B
Amgen (AMGN)$158.5B
Gilead Sciences (GILD)$134.6B
Vertex Pharmaceuticals (VRTX)$118.1B
Bristol Myers Squibb (BMY)$96.4B
CSL (CSLLY)$81.2B
GSK (GSK)$74.3B
Regeneron Pharmaceuticals (REGN)$58.6B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.4B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.3B
Illumina (ILMN)$15.2B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Incyte (INCY)$13.1B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.5B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.6B